abstract |
The invention relates to the use of a CD40 agonist for treating cancer, a pre-malignant disorder or an infectious disease,wherein a CD40 agonist is locally administered and targeted to a tumor draining lymph nodeof a subject. Optionally, a CD40 agonist is formulated in a slow-release formulation. Optionally, a CTL-activating peptide is further administered. |